Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies

Cancer Biology and Medicine

Volumn 11, Issue 1, 2014, Pages 1-19

  Phan, Liem Minh ^a   Yeung, Sai Ching Jim ^a   Lee, Mong Hong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell cycle; Energy metabolism; Glutaminolysis; Glycolysis; Mitochondria biogenesis

Indexed keywords

FATTY ACID; GLUCOSE; GLUTAMINE;

AMINO ACID METABOLISM; BIOGENESIS; CANCER CELL METABOLISM; CANCER THERAPY; CELL ENERGY; CELL METABOLISM; DIAGNOSTIC IMAGING; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUTAMINOLYSIS; GLYCOLYSIS; LIPOGENESIS; MITOCHONDRIAL BIOGENESIS; NUCLEAR MAGNETIC RESONANCE SCANNER; PENTOSE PHOSPHATE CYCLE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 84897935083     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.01.001     Document Type: Review

References (184)

1. Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Yeung S J, Pan J, Lee M H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008;65:3981-3999.
3. DeBerardinis R J, Lum J J, Hatzivassiliou G, Thompson C B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
4. DeBerardinis R J, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-19350.
5. Deberardinis R J, Sayed N, Ditsworth D, Thompson C B. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61.
6. Thompson C B, Bauer D E, Lum J J, Hatzivassiliou G, Zong W X, Zhao F, et al. How do cancer cells acquire the fuel needed to support cell growth? Cold Spring Harb Symp Quant Biol 2005;70:357-362.
7. Vander Heiden M G, Cantley L C, Thompson C B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
8. Vander Heiden M G, Plas D R, Rathmell J C, Fox C J, Harris M H, Thompson C B. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001;21:5899-5912.
9. Wise D R, DeBerardinis R J, Mancuso A, Sayed N, Zhang X Y, Pfeiffer H K, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-18787.
10. Wise D R, Thompson C B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010;35:427-433.
11. Dang C V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
12. Dang C V. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle 2009;8:3243-3245.
13. Dang C V. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 2010;9:3884-3886.
14. Dang C V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010;70:859-862.
15. Dang C V, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-6483.
16. Dang C V, Semenza G L. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
17. Ward P S, Thompson C B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
18. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift 1924;152:319-344 (German). Reprinted in English in the book On metabolism of tumors by O. Warburg, Publisher: Constable, London, 1930.
19. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270.
20. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
21. Dang C V. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc 2007;4:35-53.
22. DeBerardinis R J, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010;29:313-324.
23. Hsu P P, Sabatini D M. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-707.
24. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009;23:537-548.
25. Dang C V, Lewis B C, Dolde C, Dang G, Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 1997;29:345-354.
26. Denko N C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008;8:705-713.
27. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627-2633.
28. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008;10:611-618.
29. Bensaad K, Tsuruta A, Selak M A, Vidal M N, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-120.
30. Bensaad K, Vousden K H. p53: new roles in metabolism. Trends Cell Biol 2007;17:286-291.
31. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech 2011;4:727-732.
32. Kennedy K M, Dewhirst M W. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010;6:127-148.
33. Semenza G L. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 2008;118:3835-3837.
34. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell R G, Chiavarina B, et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010;9:3506-3514.
35. Martinez-Outschoorn U E, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011;10:1271-1286.
36. Semenza G L, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, et al. 'The metabolism of tumours': 70 years later. Novartis Found Symp 2001;240:251-260; discussion 260-4.
37. Shaw R J. Glucose metabolism and cancer. Curr Opin Cell Biol 2006;18:598-608.
38. Kim J W, Dang C V. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142-150.
39. Sandulache V C, Ow T J, Pickering C R, Frederick M J, Zhou G, Fokt I, et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 2011;117:2926-2938.
40. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521-534.
41. Gao P, Tchernyshyov I, Chang T C, Lee Y S, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-765.
42. Gangrade A, Calin G A. MicroRNAs and Cancer Hallmarks. Cancer Hallmarks 2013;1:50-57.
43. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 2010;9:3921-3932.
44. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012;53:421-436.
45. Jonas S K, Benedetto C, Flatman A, Hammond R H, Micheletti L, Riley C, et al. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspensions and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br J Cancer 1992;66:185-191.
46. Hartmannsberger D, Mack B, Eggert C, Denzel S, Stepp H, Betz C S, et al. Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett 2011;300:20-29.
47. Vizán P, Alcarraz-Vizán G, Díaz-Moralli S, Solovjeva O N, Frederiks W M, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009;124:2789-2796.
48. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011;13:310-316.
49. Gao L, Mejías R, Echevarría M, López-Barneo J. Induction of the glucose-6-phosphate dehydrogenase gene expression by chronic hypoxia in PC12 cells. FEBS Lett 2004;569:256-260.
50. Galtieri A, Tellone E, Ficarra S, Russo A, Bellocco E, Barreca D, et al. Resveratrol treatment induces redox stress in red blood cells: a possible role of caspase 3 in metabolism and anion transport. Biol Chem 2010;391:1057-1065.
51. Boros L G, Torday J S, Lim S, Bassilian S, Cascante M, Lee W N. Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res 2000;60:1183-1185.
52. Cascante M, Centelles J J, Veech R L, Lee W N, Boros L G. Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer 2000;36:150-154.
53. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006;94:578-585.
54. Porter S N, Howarth G S, Butler R N. Non-steroidal anti-inflammatory drugs and apoptosis in the gastrointestinal tract: potential role of the pentose phosphate pathways. Eur J Pharmacol 2000;397:1-9.
55. Tian W N, Braunstein L D, Apse K, Pang J, Rose M, Tian X, et al. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol 1999;276:C1121-1131.
56. Li D, Zhu Y, Tang Q, Lu H, Li H, Yang Y, et al. A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. Cancer Biother Radiopharm 2009;24:81-90.
57. Fico A, Paglialunga F, Cigliano L, Abrescia P, Verde P, Martini G, et al. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. Cell Death Differ 2004;11:823-831.
58. Pias E K, Aw T Y. Apoptosis in mitotic competent undifferentiated cells is induced by cellular redox imbalance independent of reactive oxygen species production. FASEB J 2002;16:781-790.
59. Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011;30:546-555.
60. Efferth T, Fabry U, Osieka R. DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation. J Leukoc Biol 2001;69:340-342.
61. Finn P F, Mesires N T, Vine M, Dice J F. Effects of small molecules on chaperone-mediated autophagy. Autophagy 2005;1:141-145.
62. Leopold J A, Walker J, Scribner A W, Voetsch B, Zhang Y Y, Loscalzo A J, et al. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem 2003;278:32100-6.
63. Pan S, World C J, Kovacs C J, Berk B C. Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:895-901.
64. Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J 2011;439:141-149.
65. Wallace D C. Mitochondria and cancer. Nat Rev Cancer 2012;12:685-698.
66. Cavalli L R, Varella-Garcia M, Liang B C. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 1997;8:1189-1198.
67. Desjardins P, Frost E, Morais R. Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 1985;5:1163-1169.
68. King M P, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-503.
69. Magda D, Lecane P, Prescott J, Thiemann P, Ma X, Dranchak P K, et al. mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. BMC Genomics 2008;9:521.
70. Morais R, Zinkewich-Péotti K, Parent M, Wang H, Babai F, Zollinger M. Tumor-forming ability in athymic nude mice of human cell lines devoid of mitochondrial DNA. Cancer Res 1994;54:3889-3896.
71. Weinberg F, Hamanaka R, Wheaton W W, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010;107:8788-8793.
72. Li F, Wang Y, Zeller K I, Potter J J, Wonsey D R, O'Donnell K A, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005;25:6225-6234.
73. Santos C R, Schulze A. Lipid metabolism in cancer. FEBS J 2012;279:2610-2623.
74. Medes G, Thomas A, weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13:27-29.
75. Kuhajda FP, Jenner K, Wood F D, Hennigar R A, Jacobs L B, Dick J D, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994;91:6379-6383.
76. Menendez J A, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-777.
77. Li J N, Mahmoud M A, Han W F, Ripple M, Pizer E S. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 2000;261:159-165.
78. Swinnen J V, Vanderhoydonc F, Elgamal A A, Eelen M, Vercaeren I, Joniau S, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88:176-179.
79. Yoon S, Lee M Y, Park S W, Moon J S, Koh Y K, Ahn Y H, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007;282:26122-26131.
80. Furuta E, Pai S K, Zhan R, Bandyopadhyay S, Watabe M, Mo Y Y, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008;68:1003-1011.
81. Bauer D E, Hatzivassiliou G, Zhao F, Andreadis C, Thompson C B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005;24:6314-6322.
82. Hatzivassiliou G, Zhao F, Bauer D E, Andreadis C, Shaw A N, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005;8:311-321.
83. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007;67:8180-8187.
84. Accioly M T, Pacheco P, Maya-Monteiro C M, Carrossini N, Robbs B K, Oliveira S S, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 2008;68:1732-1740.
85. Konstantinopoulos P A, Karamouzis M V, Papavassiliou A G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-555.
86. Clendening J W, Pandyra A, Boutros P C, El Ghamrasni S, Khosravi F, Trentin G A, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 2010;107:15051-15056.
87. Kornblau S M, Banker D E, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007;109:2999-3006.
88. Graf H, Jüngst C, Straub G, Dogan S, Hoffmann R T, Jakobs T, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008;78:34-38.
89. Kodach L L, Jacobs R J, Voorneveld P W, Wildenberg M E, Verspaget H W, van Wezel T, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011;60:1544-1553.
90. Horton J D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 2002;30:1091-1095.
91. Hardie D G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-785.
92. Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, et al. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 2009;15:255-269.
93. Freed-Pastor W A, Mizuno H, Zhao X, Langerød A, Moon S H, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-258.
94. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011;1:442-456.
95. Samuel V T, Shulman G I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148:852-871.
96. Renehan A G, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-336.
97. Rosenzweig S A, Atreya H S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 2010;80:1115-1124.
98. Shoelson S E, Lee J, Goldfine A B. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
99. Kalaany N Y, Sabatini D M. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009;458:725-731.
100. Sell Ch. Caloric restriction and insulin-like growth factors in aging and cancer. Horm Metab Res 2003;35:705-711.
101. Carracedo A, Cantley L C, Pandolfi P P. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013;13:227-232.
102. Singh R, Cuervo A M. Lipophagy: connecting autophagy and lipid metabolism. Int J Cell Biol 2012;2012:282041.
103. Chiarugi A, Dölle C, Felici R, Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer 2012;12:741-752.
104. Pike LS, Smift A L, Croteau N J, Ferrick D A, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 2011;1807:726-734.
105. Hosokawa K, Arai F, Yoshihara H, Nakamura Y, Gomei Y, Iwasaki H, et al. Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. Biochem Biophys Res Commun 2007;363:578-583.
106. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006;12:446-451.
107. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004;431:997-1002.
108. Jeon S M, Chandel N S, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012;485:661-665.
109. Mihaylova M M, Shaw R J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011;13:1016-1023.
110. Diradourian C, Girard J, Pégorier J P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005;87:33-38.
111. Zaugg K, Yao Y, Reilly P T, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011;25:1041-1051.
112. Schafer Z T, Grassian A R, Song L, Jiang Z, Gerhart-Hines Z, Irie H Y, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461:109-113.
113. Carracedo A, Weiss D, Leliaert A K, Bhasin M, de Boer V C, Laurent G, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest 2012;122:3088-3100.
114. Giordano A, Calvani M, Petillo O, Grippo P, Tuccillo F, Melone M A, et al. tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1. Cell Death Differ 2005;12:603-613.
115. Paumen M B, Ishida Y, Han H, Muramatsu M, Eguchi Y, Tsujimoto Y, et al. Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun 1997;231:523-525.
116. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010;120:142-156.
117. Vickers A E. Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. Toxicol Pathol 2009;37:78-88.
118. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008;68:5198-5205.
119. Hu J, Locasale J W, Bielas J H, O'Sullivan J, Sheahan K, Cantley L C, et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 2013;31:522-529.
120. Kurhanewicz J, Vigneron D B, Brindle K, Chekmenev E Y, Comment A, Cunningham C H, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011;13:81-97.
121. Nahmias C, Carlson E R, Duncan L D, Blodgett T M, Kennedy J, Long M J, et al. Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. J Oral Maxillofac Surg 2007;65:2524-2535.
122. Blodgett T M, Meltzer C C, Townsend D W. PET/CT: form and function. Radiology 2007;242:360-385.
123. Talbot J N, Gutman F, Fartoux L, Grange J D, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285-1289.
124. Kubota K, Furumoto S, Iwata R, Fukuda H, Kawamura K, Ishiwata K. Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med 2006;20:527-533.
125. Breeuwsma A J, Pruim J, van den Bergh A C, Leliveld A M, Nijman R J, Dierckx R A, et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010;77:160-164.
126. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009;50:1585-1593.
127. Buck A K, Herrmann K, Shen C, Dechow T, Schwaiger M, Wester H J. Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. Methods 2009;48:205-215.
128. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-1626.
129. Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 2013;54:499-506.
130. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:54-63.
131. Wagner B, Anton M, Nekolla S G, Reder S, Henke J, Seidl S, et al. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. J Am Coll Cardiol 2006;48:2107-2115.
132. Chuang C F, Chan A A, Larson D, Verhey L J, McDermott M, Nelson S J, et al. Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. Technol Cancer Res Treat 2007;6:375-382.
133. Kurhanewicz J, Vigneron D B. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 2008;16:697-710, ix-x.
134. Mountford C, Ramadan S, Stanwell P, Malycha P. Proton MRS of the breast in the clinical setting. NMR Biomed 2009;22:54-64.
135. Geraghty P R, van den Bosch M A, Spielman D M, Hunjan S, Birdwell R L, Fong K J, et al. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma. Breast J 2008;14:574-580.
136. Glunde K, Ackerstaff E, Mori N, Jacobs M A, Bhujwalla Z M. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006;3:496-506.
137. Haddadin I S, McIntosh A, Meisamy S, Corum C, Styczynski Snyder A L, Powell N J, et al. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 2009;22:65-76.
138. Nelson S J, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron D B, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464-476.
139. Gillies R J, Morse D L. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005;7:287-326.
140. Chen J, Huang S L, Li T, Chen X L. In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology 2006;48:312-318.
141. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W. Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol 2005;12:51-57.
142. McKnight T R, Lamborn K R, Love T D, Berger M S, Chang S, Dillon W P, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg 2007;106:660-666.
143. Spampinato M V, Smith J K, Kwock L, Ewend M, Grimme J D, Camacho D L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204-212.
144. 13C]pyruvate. Sci Transl Med 2013;5:198ra108.
145. Sardanelli F, Fausto A, Podo F. MR spectroscopy of the breast. Radiol Med 2008;113:56-64.
146. Kwock L, Smith J K, Castillo M, Ewend M G, Cush S, Hensing T, et al. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat 2002;1:17-28.
147. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 2011;50:10764-10770.
148. Wang J B, Erickson J W, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-219.
149. Le A, Lane A N, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012;15:110-121.
150. Jiang J K, Boxer M B, Vander Heiden M G, Shen M, Skoumbourdis A P, Southall N, et al. Evaluation of thieno[3, 2-b]pyrrole[3, 2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett 2010;20:3387-3393.
151. Israelsen W J, Dayton T L, Davidson S M, Fiske B P, Hosios A M, Bellinger G, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013;155:397-409.
152. Zhou W, Simpson P J, McFadden J M, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003;63:7330-7337.
153. Brahimi-Horn M C, Bellot G, Pouysségur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011;21:67-72.
154. Morris J C, Chiche J, Grellier C, Lopez M, Bornaghi L F, Maresca A, et al. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem 2011;54:6905-6918.
155. Semenza G L. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010;20:51-56.
156. Semenza G L. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148:399-408.
157. Fang J, Quinones Q J, Holman T L, Morowitz M J, Wang Q, Zhao H, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 2006;70:2108-2115.
158. Sonveaux P, Végran F, Schroeder T, Wergin M C, Verrax J, Rabbani Z N, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008;118:3930-3942.
159. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007;109:3812-3819.
160. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang K Y, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011;102:1007-1013.
161. Michelakis E D, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31ra34.
162. Papandreou I, Goliasova T, Denko N C. Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? Int J Cancer 2011;128:1001-1008.
163. Bonnet S, Archer S L, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
164. Le A, Cooper C R, Gouw A M, Dinavahi R, Maitra A, Deck L M, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010;107:2037-2042.
165. Maher J C, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis T J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 2007;6:732-741.
166. Pelicano H, Martin D S, Xu R H, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-4646.
167. Shaw R J, Lamia K A, Vasquez D, Koo S H, Bardeesy N, Depinho R A, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-1646.
168. Evans J M, Donnelly L A, Emslie-Smith A M, Alessi D R, Morris A D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.
169. Bowker S L, Majumdar S R, Veugelers P, Johnson J A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006;29:1990-1991.
170. Hirsch H A, Iliopoulos D, Tsichlis P N, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-7511.
171. Dahabreh I J, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303.
172. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
173. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105.
174. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-1559.
175. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008;7:110-120.
176. Derst C, Henseling J, Röhm K H. Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 2000;9:2009-2017.
177. Bach S J, Swaine D. The effect of arginase on the retardation of tumour growth. Br J Cancer 1965;19:379-386.
178. Ni Y, Schwaneberg U, Sun Z H. Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008;261:1-11.
179. Neuman R E, Mccoy T A. Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine. Science 1956;124:124-125.
180. Ardawi M S, Newsholme E A. Glutamine metabolism in lymphocytes of the rat. Biochem J 1983;212:835-842.
181. Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 2009;4:e7897.
182. Holen K, Saltz L B, Hollywood E, Burk K, Hanauske A R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.
183. Wen Y Y, Chou P C, Phan L, Su C H, Chen J, Hsieh Y C, Xue Y W, et al. DNA Damage-Mediated c-Myc Degradation Requires 14-3-3 Sigma. Cancer Hallmarks 2013;1:3-17.
184. Dang C V. Links between metabolism and cancer. Genes Dev 2012;26:877-890.